Official Title
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Phase
Phase 3Lead Sponsor
Leo PharmaStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Actinic KeratosisIntervention/Treatment
ingenol mebutate ...Study Participants
373The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment.
Inclusion Criteria: Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on the full balding scalp (the balding part of the scalp should be greater than 25 cm2 (4 in2) and up to approximately 250 cm2 (40 In2) Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 In2). The tracking area must be within the treatment area Exclusion Criteria: Location of the treatment area (full balding scalp) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC Treatment with ingenol mebutate gel in the treatment area within the last 12 months Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions) History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosum)
| Event Type | Organ System | Event Term | LEO 43204 0.037% Gel | Vehicle Gel | LEO 43204 0.037% Gel - Extended Follow-up | Vehicle Gel - Extended Follow-up |
|---|
The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1 (baseline), Week 4 and Week 8. Complete clearance was defined as no clinically visible AKs in the treatment area.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
Partial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.
The percent reduction at Week 8 from baseline was analysed using a negative binomial regression for the AK count at Week 8 with treatment group and pooled sites as factors and baseline count as offset variable. The table presents adjusted mean percent reduction at Week 8 from baseline.
